# psoriasis - gemini-3.6-flash

- Benchmark system: raw
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 5409
- Completion tokens: 7609
- Reasoning tokens: 
- Total tokens: 13018
- API requests reported: 
- Elapsed seconds: 16.718
- Final benchmark system: raw; file rank 2/5; original repeat 2; model vendor: Google Gemini

---
### 1. Overall Biological Interpretation

The transcriptomic profile of psoriatic lesional skin compared to normal control skin reflects a highly synchronized, multi-cellular inflammatory state characterized by profound alteration of epidermal differentiation and robust activation of innate and adaptive immune circuits. 

The primary biological theme centered in this dataset is the activation of the **IL-36 / IL-17 inflammatory axis**, characterized by massive upregulation of proinflammatory cytokines (*IL36A*, *IL36G*, *IL19*, *IL20*, *IL26*) alongside the regulatory counter-antagonist *IL36RN*. This cytokine cascade drives two predominant downstream effector programs within the epidermis:

1. **Aberrant Keratinocyte Differentiation and Epidermal Hyperplasia:** Marked by significant upregulation of cornified envelope genes (*SPRR2A/B/D/E/F/G*, *SPRR3*, *LCE3A*, *LCE3D*), hyperproliferation-associated cytokeratins (*KRT6A*), gap junction proteins (*GJB2*, *GJB6*), and cell-cycle regulators (*RRM2*, *CCNE1*). Concurrently, normal epidermal growth factor signaling mediators such as betacellulin (*BTC*) are markedly suppressed.
2. **Amplified Innate & Antimicrobial Defense:** High expression of beta-defensins (*DEFB4A*, *DEFB4B*, *DEFB103A*, *DEFB103B*), S100 alarmins (*S100A7*, *S100A7A*, *S100A8*, *S100A12*), peptidase inhibitors (*PI3*, *SERPINB3*, *SERPINB4*), and chemoattractants (*CXCL13*, *CXCR2*).

Additionally, alterations in metabolic pathways—including tryptophan metabolism (*KYNU*), lipid homeostasis (*FABP5*, *PLA2G4D*, *PLA2G4E*, *ABCG4*), and xenobiotic/redox regulation (*VNN3P*, *AKR1B10*, *AKR1B15*)—highlight a systemic reprogramming of keratinocyte metabolism to sustain chronic inflammation and tissue remodeling.

---

### 2. Core Biological Programs

```
                  +----------------------------------------+
                  |  Psoriatic Lesional Skin Transcriptome |
                  +-------------------+--------------------+
                                      |
       +------------------------------+------------------------------+
       |                              |                              |
       v                              v                              v
[Program 1: IL-36/IL-17]    [Program 2: Keratinization]   [Program 3: Antimicrobial]
(IL36A, IL36G, IL19, IL20)  (SPRR2/3, LCE3A/D, KRT6A)     (DEFB4A/B, S100A7/8/12)
       |                              |                              |
       +------------------------------+------------------------------+
                                      |
                                      v
                        [Program 4: Protease Dynamics]
                        (SERPINB3/4, PI3, TMPRSS11D)
```

#### Program 1: IL-36 and Proinflammatory Cytokine Signaling Cascade
* **Direction:** Strongly Upregulated
* **Major Supporting Genes:** *IL36A* (log2FC 11.37), *IL36G* (log2FC 5.68), *IL19* (log2FC 7.58), *IL20* (log2FC 5.67), *IL26* (log2FC 4.36), *IL36RN* (log2FC 3.01), *IRAK2* (log2FC 2.08), *ZC3H12A* (log2FC 3.85)
* **Standardized Pathway:** Reactome: *Interleukin-36 signaling* (R-HSA-9020597) / KEGG: *IL-17 signaling pathway* (hsa04657)
* **Biological Rationale:** *IL36A* and *IL36G* are key driver cytokines in psoriasis that bind the IL-36 receptor, activating NF-κB and MAPK pathways via *IRAK2*. Up-regulation of *IL19* and *IL20* (members of the IL-10 cytokine family) further amplifies keratinocyte hyperproliferation in an autocrine loop. *IL36RN* upregulation represents a negative feedback mechanism that is overwhelmed by the agonist excess.
* **Evidence Strength & Limitations:** **High evidence strength.** Supported by multiple independent cytokine and intracellular transducer genes showing extremely low FDR values ($< 10^{-60}$). Limitation: Protein-level functional stoichiometry between IL-36 agonists and the antagonist (*IL36RN*) cannot be directly inferred from RNA expression alone.

#### Program 2: Epidermal Keratinization and Cornified Envelope Assembly
* **Direction:** Strongly Upregulated
* **Major Supporting Genes:** *SPRR2A* (log2FC 7.31), *SPRR2B* (log2FC 6.38), *SPRR2D* (log2FC 5.92), *SPRR2E* (log2FC 3.99), *SPRR2F* (log2FC 7.22), *SPRR2G* (log2FC 4.75), *SPRR3* (log2FC 7.18), *LCE3A* (log2FC 8.30), *LCE3D* (log2FC 5.31), *KRT6A* (log2FC 4.30), *GJB2* (log2FC 4.42), *GJB6* (log2FC 3.02)
* **Standardized Pathway:** GO: Biological Process: *Keratinization* (GO:0031424) / *Cornified envelope formation* (GO:0001533)
* **Biological Rationale:** Small proline-rich proteins (SPRRs) and late cornified envelope proteins (LCEs) serve as precursor structures cross-linked by transglutaminases during terminal differentiation. Overexpression of these genes, combined with *KRT6A* (a marker of activated/hyperproliferative keratinocytes) and gap junction channel genes (*GJB2/GJB6*), directly reflects the histological hallmark of psoriatic plaques: acanthosis and altered differentiation.
* **Evidence Strength & Limitations:** **Very High evidence strength.** Massive gene co-expression of the contiguous *SPRR* and *LCE* gene clusters on chromosome 1q21 (Epidermal Differentiation Complex). Limitation: Spatial resolution across epidermal layers is absent in bulk RNA profiling.

#### Program 3: Innate Antimicrobial and Alarmin Response
* **Direction:** Upregulated
* **Major Supporting Genes:** *DEFB4A* (log2FC 11.18), *DEFB4B* (log2FC 11.03), *DEFB103A* (log2FC 5.76), *DEFB103B* (log2FC 5.75), *S100A7* (log2FC 7.09), *S100A7A* (log2FC 9.83), *S100A8* (log2FC 7.73), *S100A12* (log2FC 8.33), *PI3* (log2FC 9.24)
* **Standardized Pathway:** GO: Biological Process: *Antimicrobial humoral response* (GO:0019730) / *Defense response to bacterium* (GO:0042742)
* **Biological Rationale:** Human beta-defensins (*DEFB4A/B*, *DEFB103A/B*) and S100 proteins (*S100A7/8/12*) act as microbicides and endogenous danger-associated molecular patterns (DAMPs). *PI3* (Peptidase Inhibitor 3 / Elafin) protects host tissues from neutrophil elastase during cutaneous inflammation. Their concurrent upregulation illustrates host defense hyper-activation driven by keratinocyte-derived signals.
* **Evidence Strength & Limitations:** **Very High evidence strength.** Supported by several of the most strongly upregulated genes in the dataset ($> 100$-fold change). Limitation: Gene duplications (e.g., *DEFB4A* vs *DEFB4B*) can create alignment artifacts in RNA-seq, though true biology is established.

#### Program 4: Protease and Serine Protease Inhibitor Balance
* **Direction:** Strongly Upregulated
* **Major Supporting Genes:** *SERPINB3* (log2FC 6.74), *SERPINB4* (log2FC 9.12), *SERPINB11* (log2FC 4.47), *SERPINB13* (log2FC 3.09), *TMPRSS11D* (log2FC 7.75), *PRSS27* (log2FC 4.24), *KLK13* (log2FC 4.05)
* **Standardized Pathway:** GO: Biological Process: *Regulation of endopeptidase activity* (GO:0052547) / Reactome: *Serpin-mediated regulation of proteolysis* (R-HSA-5578762)
* **Biological Rationale:** Skin homeostasis relies on a tight equilibrium between serine proteases (such as *TMPRSS11D*, *PRSS27*, *KLK13*, involved in desquamation and pro-cytokine cleavage) and clade B serpins (*SERPINB3*, *SERPINB4*, which inhibit cysteine and serine peptidases). The coordinate surge in both proteases and anti-proteases indicates extensive extracellular matrix remodeling and altered epidermal barrier turnover.
* **Evidence Strength & Limitations:** **High evidence strength.** Consistently observed across multiple clade members. Limitation: Protease activity is regulated post-translationally by zymogen cleavage; transcript abundance does not equal enzymatic catalytic rate.

#### Program 5: Dysregulated Epidermal Homeostasis & Suppressed Differentiation Signaling
* **Direction:** Downregulated
* **Major Supporting Genes:** *BTC* (log2FC -4.29), *CYP2W1* (log2FC -4.70), *SAPCD1* (log2FC -2.94), *WAKMAR1* (log2FC -5.63), *LOC107984452* (log2FC -6.25)
* **Standardized Pathway:** GO: Biological Process: *Epidermal growth factor receptor signaling pathway* (GO:0007173) / *Xenobiotic metabolic process* (GO:0006805)
* **Biological Rationale:** Betacellulin (*BTC*), an EGFR ligand expressed in normal skin, is downregulated during chronic psoriatic lesion formation, shifting the EGFR ligand balance toward hyper-proliferative ligands (e.g., AREG, TGFA). Concurrently, cytochrome P450 enzymes (*CYP2W1*) and regulatory non-coding RNAs (*WAKMAR1*, a lncRNA implicated in wound healing and keratinocyte migration) are suppressed, reflecting loss of homeostatic epidermal differentiation circuits.
* **Evidence Strength & Limitations:** **Moderate evidence strength.** Derived from fewer distinct gene families than the upregulated pathways. Limitation: Downregulated signals in tissue transcriptomics often reflect shifts in cell-type proportions (loss of differentiated suprabasal states relative to proliferating basal states).

---

### 3. Key Genes and Interaction Modules

```
+-----------------------------------------------------------------------------------+
| Key Modules & Interacting Candidates                                              |
+-------------------+--------------------------------+------------------------------+
| Candidate / Gene  | Direction in Data              | Module / Interaction Type    |
+-------------------+--------------------------------+------------------------------+
| IL36A / IL36G     | Upregulated (FC ~2,600 / ~50)  | Pathway co-membership /      |
|                   |                                | Regulatory loop              |
| DEFB4A / DEFB4B   | Upregulated (FC ~2,300)        | Gene duplication /           |
|                   |                                | Co-expression                |
| SPRR Cluster      | Upregulated (FC ~15-160)       | Genomic cluster co-expression|
| SERPINB3 / 4      | Upregulated (FC ~100 / ~550)   | Functional co-membership     |
| KYNU              | Upregulated (FC ~21)           | Metabolic regulation         |
| BTC               | Downregulated (FC ~1/20)       | Direct receptor-ligand loss  |
| CXCL13 / CXCR2    | Upregulated (FC ~60 / ~6.5)    | Ligand-receptor pair /       |
|                   |                                | Immune cell recruitment      |
| ZC3H12A (Regnase) | Upregulated (FC ~14)           | Post-transcriptional regulator|
+-------------------+--------------------------------+------------------------------+
```

1. **IL36A / IL36G / IL36RN Module**
   * **Direction:** Strongly Upregulated (*IL36A*: log2FC 11.37, *IL36G*: 5.68, *IL36RN*: 3.01).
   * **Role:** Primary upstream immune driver.
   * **Interaction Nature:** **Pathway co-membership & regulatory loop.** *IL36A* and *IL36G* bind the common IL-36R receptor complex, initiating downstream NF-κB signaling. *IL36RN* competitively binds IL-36R to block signal transduction.

2. **DEFB4A / DEFB4B Module**
   * **Direction:** Strongly Upregulated (*DEFB4A*: log2FC 11.18, *DEFB4B*: 11.03).
   * **Role:** Primary antimicrobial effector defense.
   * **Interaction Nature:** **Co-expression / Structural paralogs.** Derived from copy number variable tandem duplications on 8p23.1; they encode identical or near-identical peptide products functioning via direct membrane disruption of pathogens and chemokine receptor engagement (CCR6).

3. **SPRR2 / SPRR3 Differentiation Complex**
   * **Direction:** Upregulated (log2FC range 3.99 to 7.31).
   * **Role:** Structural cross-linking of the envelope in keratinocytes.
   * **Interaction Nature:** **Genomic cluster co-expression.** Located in the Epidermal Differentiation Complex (EDC) on chromosome 1q21. Undergo synchronized transcriptional activation by AP-1 and C/EBP transcription factors downstream of IL-17/IL-36 signaling.

4. **SERPINB3 / SERPINB4 Axis**
   * **Direction:** Strongly Upregulated (*SERPINB3*: log2FC 6.74, *SERPINB4*: 9.12).
   * **Role:** Protection against endogenous/exogenous proteolysis and auto-inflammation inhibition.
   * **Interaction Nature:** **Co-expression and functional pathway co-membership.** Both target cathepsins and proteases; *SERPINB4* specifically targets chymotrypsin-like proteases.

5. **KYNU (Kynureninase)**
   * **Direction:** Upregulated (log2FC 4.42, $P = 7.18 \times 10^{-95}$).
   * **Role:** Tryptophan catabolism along the kynurenine pathway.
   * **Interaction Nature:** **Regulatory interaction.** Induced by IFN-gamma and TNF in keratinocytes and dendritic cells; depletes tryptophan and produces bioactive metabolites (3-hydroxyanthranilic acid) modulating T-cell responses.

6. **BTC (Betacellulin)**
   * **Direction:** Downregulated (log2FC -4.29, $P = 2.37 \times 10^{-76}$).
   * **Role:** Epidermal growth factor receptor (EGFR/ERBB4) ligand maintaining normal skin differentiation.
   * **Interaction Nature:** **Ligand-receptor pair (Indirect loss of normal signaling).** Inverse correlation with pro-inflammatory cytokines (*IL36A*, *IL19*).

7. **CXCL13 / CXCR2 Axis**
   * **Direction:** Upregulated (*CXCL13*: log2FC 5.89; *CXCR2*: log2FC 2.70).
   * **Role:** Chemotactic recruitment of B cells (*CXCL13*) and neutrophils (*CXCR2* ligands).
   * **Interaction Nature:** **Pathway co-membership / Cellular co-habitation signal.** Reflects the infiltration of inflammatory leukocytes into lesional skin.

8. **ZC3H12A (Regnase-1)**
   * **Direction:** Upregulated (log2FC 3.85, $P = 3.95 \times 10^{-74}$).
   * **Role:** Endoribonuclease responsible for decay of inflammatory mRNAs (e.g., *IL6*, *IL36G*).
   * **Interaction Nature:** **Negative feedback regulatory interaction.** Transcriptional induction by IL-17/TNF serves to restrain excessive inflammatory mRNA stability.

9. **VNN3P (VNN3 Pseudogene / Vanin 3)**
   * **Direction:** Upregulated (log2FC 8.28, $P = 1.35 \times 10^{-150}$).
   * **Role:** Pantetheinase activity involved in oxidative stress responses and coenzyme A metabolism.
   * **Interaction Nature:** **Co-expression with alarmin module.** Strong marker of inflammatory skin activation, though precise protein-coding status/function requires confirmation due to pseudogene annotation.

10. **AKR1B10 / AKR1B15 Module**
    * **Direction:** Upregulated (*AKR1B10*: log2FC 6.27, *AKR1B15*: log2FC 5.23).
    * **Role:** Aldose reductases handling retinoic acid, lipid peroxidation products, and carbonyl detoxification.
    * **Interaction Nature:** **Pathway co-membership (Metabolic detox).** Induced by NRF2 and inflammatory signaling in hyperproliferative epithelia.

---

### 4. Validation Priorities

```
+--------------------------------------------------------------------------------------------------------+
| Priority | Category          | Target / Signal       | Proposed Next Step      | Level of Evidence   |
+----------+-------------------+-----------------------+-------------------------+---------------------+
| 1        | Therapeutic Target| IL-36 Axis            | Receptor blocking assay | Established         |
|          |                   | (IL36A/IL36G/IL36RN)  | (3D skin models)        | Evidence            |
| 2        | Mechanistic       | SERPINB3/B4 Protease  | Enzymatic cleavage      | Supported           |
|          | Hypothesis        | Balance               | profiling (Zymography)  | Hypothesis          |
| 3        | Biomarker         | DEFB4A/S100A7A/PI3    | Serum / Tape-strip      | Supported           |
|          |                   | Panel                 | ELISA validation        | Hypothesis          |
| 4        | Network           | KYNU Tryptophan       | Metabolomic profiling   | Supported           |
|          | Hypothesis        | Pathway               | (LC-MS kynurenine)      | Hypothesis          |
| 5        | Composition Check | BTC Suppression vs    | Single-cell RNA-seq     | Exploratory         |
|          |                   | Keratinocyte Identity | (scRNA-seq mapping)     | Hypothesis          |
+--------------------------------------------------------------------------------------------------------+
```

#### Priority 1: Functional Neutralization of the IL-36 Autocrine Feedback Loop
* **Category:** Therapeutic Target / Mechanistic Hypothesis
* **Rationale for Prioritization:** *IL36A* (log2FC 11.37) and *IL36G* (log2FC 5.68) show some of the largest fold-change values in the dataset. While anti-IL-36R therapy (e.g., spesolimab) is approved for generalized pustular psoriasis, its comparative potency in plaque psoriasis subtypes remains an active area of investigation.
* **Current Data Evidence:** Extremely high log2FC values with negligible FDR ($< 10^{-90}$) for both agonists and their antagonist *IL36RN*.
* **External Evidence:** Human genetic mutations in *IL36RN* cause severe generalized pustular psoriasis (DITRA). Knockout skin models exhibit reduced IL-17-mediated tissue pathology.
* **Recommended Next Step:** Target validation using patient-derived 3D organotypic skin equivalents stimulated with IL-17A, applying anti-IL-36R neutralizing antibodies to assess reversal of the *SPRR*, *LCE*, and *DEFB* gene modules.
* **Evidence Level:** **Established Evidence** (for disease association); **Supported Hypothesis** (for broad plaque psoriasis efficacy).

#### Priority 2: Protease-Antiprotease Balance Mediated by SERPINB3/B4
* **Category:** Mechanistic Hypothesis
* **Rationale for Prioritization:** Massive upregulation of *SERPINB4* (log2FC 9.12) and *SERPINB3* (log2FC 6.74) accompanied by altered protease expression (*TMPRSS11D*, *KLK13*, *PRSS27*) suggests an active extracellular remodeling dynamic that may control auto-antigen generation or cytokine cleavage.
* **Current Data Evidence:** High statistical significance ($P < 10^{-64}$) across multiple serpins and kallikrein-family proteases.
* **External Evidence:** SERPINB3/B4 inhibit cathepsins and suppress apoptosis, potentially prolonging keratinocyte survival in lesions.
* **Recommended Next Step:** Functional zymography and substrate cleavage assays in primary keratinocytes under SERPINB3/B4 knockdown to determine if their inhibition restores normal desquamation and apoptosis.
* **Evidence Level:** **Supported Hypothesis.**

#### Priority 3: Non-Invasive Biomarker Panel (DEFB4A, S100A7A, PI3)
* **Category:** Biomarker
* **Rationale for Prioritization:** Secreted proteins with massive log2FC upregulation ($> 9$ to 11 log2FC) are prime candidates for minimally invasive disease severity markers or treatment response indicators.
* **Current Data Evidence:** Top-ranking differential expression significance ($P < 10^{-65}$) in lesional tissue.
* **External Evidence:** Serum S100A8/A9 and DEFB4 levels correlate with Psoriasis Area and Severity Index (PASI) scores during biologic therapy.
* **Recommended Next Step:** Validate transcript-to-protein correlation in stratum corneum tape-strips and serum samples across a prospective cohort before and after targeted treatment (e.g., anti-IL-23 or anti-IL-17).
* **Evidence Level:** **Supported Hypothesis.**

#### Priority 4: Kynurenine Pathway Activation via KYNU
* **Category:** Interaction / Network Hypothesis
* **Rationale for Prioritization:** *KYNU* upregulation (log2FC 4.42, $P = 7.18 \times 10^{-95}$) implicates altered tryptophan metabolism in the lesional microenvironment.
* **Current Data Evidence:** Robust upregulation of *KYNU* within a predominantly epithelial transcriptomic signature.
* **External Evidence:** Kynurenine metabolites modulate aryl hydrocarbon receptor (AhR) signaling and T-cell differentiation (Treg vs Th17 balance).
* **Recommended Next Step:** Target quantitative LC-MS/MS metabolomics on lesional vs non-lesional skin biopsies to quantify tryptophan depletion and kynurenine metabolite accumulation.
* **Evidence Level:** **Supported Hypothesis.**

#### Priority 5: Betacellulin (BTC) Downregulation and Basal Keratinocyte Homeostasis
* **Category:** Confounding / Composition Check
* **Rationale for Prioritization:** *BTC* is one of the few strongly downregulated genes (log2FC -4.29). Resolving whether this represents active transcriptional repression or cellular loss of specific differentiated keratinocyte layers is critical.
* **Current Data Evidence:** Strong downregulation ($P = 2.37 \times 10^{-76}$).
* **External Evidence:** Loss of regular EGFR ligand balances disrupts normal suprabasal maturation.
* **Recommended Next Step:** Single-cell RNA sequencing (scRNA-seq) or spatial transcriptomics to resolve whether *BTC* expression is shut down across all epidermal layers or restricted to a specific loss of mature suprabasal keratinocyte subsets.
* **Evidence Level:** **Exploratory Hypothesis.**

---

### 5. Evidence Grounding

| Major Finding / Gene | Direct Input Data Evidence | Ontology / Pathway Evidence | Independent Literature / External Evidence | Integration / Confidence Assessment |
| :--- | :--- | :--- | :--- | :--- |
| **IL-36 Agonist Upregulation** (*IL36A*, *IL36G*) | Strongest upregulation in dataset (log2FC 11.37 & 5.68; FDR $< 10^{-90}$) | High enrichment in Reactome *IL-36 Signaling* | Overlapping: Genetic mutations in GPP; established role in inflammatory skin diseases | **High Confidence:** Multi-gene representation supported by independent functional literature. |
| **Antimicrobial Peptide Induction** (*DEFB4A/B*, *S100A7/8/12*) | Multiple genes with log2FC 7.0–11.18; FDR $< 10^{-60}$ | High enrichment in GO *Antimicrobial Humoral Response* | Overlapping: Well-characterized protein-level abundance in psoriatic scale | **High Confidence:** Convergent transcript and literature evidence. |
| **Cornified Envelope Alterations** (*SPRR*, *LCE* clusters) | $> 10$ genes within EDC locus upregulated simultaneously | High enrichment in GO *Keratinization* | Partially Independent: Chromosomal locus co-regulation vs protein incorporation into cornified envelope | **High Confidence:** Coordinated gene-cluster expression reflects tissue remodeling. |
| **EGFR Ligand Suppression** (*BTC*) | Significant downregulation (log2FC -4.29, FDR $< 10^{-73}$) | Enrichment in *EGFR signaling* | Overlapping: Altered EGFR signaling reported in hyperproliferative skin | **Moderate Confidence:** Downregulation signal requires cell-type deconvolution. |
| **Tryptophan Metabolism** (*KYNU*) | Single highly significant metabolic enzyme (log2FC 4.42, FDR $< 10^{-90}$) | KEGG *Tryptophan Metabolism* | Independent: AhR ligand generation literature in immunology | **Moderate Confidence:** Single-gene anchor; requires metabolic enzyme activity verification. |

---

### 6. Limitations and Alternative Explanations

1. **Cell-Composition Shifts vs. Cell-Intrinsic Transcriptional Changes:**
   * *Limitation:* Psoriatic lesional skin exhibits massive epidermal hyperplasia (acanthosis), elongation of rete ridges, loss of the granular layer, and invasion of neutrophils, T-cells, and dendritic cells.
   * *Impact:* High fold-changes for genes like *CXCL13*, *CXCR2*, or neutrophil-derived *S100A8/A9* may reflect an increased proportion of infiltrating immune cells rather than transcriptional induction per cell. Downregulation of *BTC* or *CYP2W1* may reflect the relative dilution of specific differentiated keratinocyte populations.
   * *Resolution:* Perform single-cell RNA sequencing (scRNA-seq) or computational cell-type deconvolution (e.g., CIBERSORTx) using skin single-cell reference panels.

2. **Absence of Non-Lesional Patient Control Skin:**
   * *Limitation:* The study design compares psoriatic lesional skin directly to normal control skin from healthy individuals.
   * *Impact:* This comparison captures both systemic genetic background differences and local tissue lesion drivers. It cannot distinguish baseline systemic skin alterations ("uninvolved/non-lesional skin state") from lesion-specific changes.
   * *Resolution:* Include paired non-lesional skin biopsies from the same psoriasis patients as an intermediate comparator group.

3. **Broad Genomic Locus Co-Regulation (EDC Chromosome 1q21):**
   * *Limitation:* Numerous top upregulated genes (*SPRR2A-G*, *SPRR3*, *LCE3A/D*, *S100A7/8/12*) reside within the Epidermal Differentiation Complex on chromosome 1q21.
   * *Impact:* Co-expression may be driven by broad regional chromatin opening (epigenetic remodeling) rather than independent functional selection of each individual protein product.
   * *Resolution:* Evaluate chromatin accessibility (ATAC-seq) across the 1q21 locus alongside transcription factor binding (ChIP-seq for AP-1, STAT3, NF-κB).

4. **RNA to Functional Protein Disconnect in Protease-Inhibitor Dynamics:**
   * *Limitation:* Serine proteases (*TMPRSS11D*, *KLK13*) and inhibitors (*SERPINB3/4*) are heavily regulated via zymogen activation, protein stability, and irreversible covalent complex formation.
   * *Impact:* mRNA expression level does not reliably predict net proteolytic activity in the extracellular matrix.
   * *Resolution:* Conduct targeted activity-based protein profiling (ABPP) or fluorogenic substrate cleavage assays in fresh tissue lysates.

5. **Pseudogene Annotation Ambiguity (*VNN3P*):**
   * *Limitation:* The top statistically significant gene in the dataset (*VNN3P*, FDR $2.63 \times 10^{-146}$) is annotated as a pseudogene in several reference databases.
   * *Impact:* Sequence alignment cross-talk between functional *VNN1*/*VNN2* genes and *VNN3P* pseudogene transcripts can skew quantification accuracy in RNA-seq pipelines.
   * *Resolution:* Re-align reads using stringent mapping parameters and validate transcript identity via long-read sequencing (Iso-Seq) or specific RT-qPCR primers designed against distinct polymorphic sites.
